Skip to main content

Advertisement

Table 1 Questions answered relevant to the management of bronchiolitis

From: The management of children with bronchiolitis in the Australasian hospital setting: development of a clinical practice guideline

Number Question
1 In infants presenting to hospital what factors in history and physical examination contribute to a differential diagnosis of bronchiolitis?
2 In infants presenting to hospital with bronchiolitis, what are the risk factors for admission or severe disease (e.g. prolonged length of hospital stay, intensive care unit (ICU) admission, and death)?
3 In infants presenting to hospital or hospitalised with bronchiolitis, does performing a CXR beneficially change medical management or clinically relevant end-points?
4 In infants presenting to hospital or hospitalised with bronchiolitis, does performing laboratory tests (blood and/or urine) beneficially change medical management or clinically relevant end-points?
5 In infants presenting to hospital or hospitalised with bronchiolitis, does performing virological investigations beneficially change medical management or clinically relevant end-points?
6 For infants presenting to hospital or hospitalised with bronchiolitis, does use of a bronchiolitis scoring system beneficially change medical management or clinically relevant end-points?
7 For infants presenting to hospital or hospitalised with bronchiolitis, what criteria should be used for safe discharge?
8a. i) In infants presenting to hospital or hospitalised with bronchiolitis, does administration of Beta2 Agonists (nebulisation, aerosol, oral or IV) improve clinically relevant end-points?
8a. ii) In older infants presenting to hospital or hospitalised with bronchiolitis, does administration of Beta2 Agonists (nebulisation, aerosol, oral or IV) improve clinically relevant end-points?
8b. i) In infants presenting to hospital or hospitalised with bronchiolitis, with a personal or family history of atopy, does administration of Beta2 Agonists (nebulisation, aerosol, oral or IV) improve clinically relevant end-points?
8b. ii) In older infants presenting to hospital or hospitalised with bronchiolitis, with a second or subsequent episode/s of bronchiolitis or wheeze, does administration of Beta2 Agonists (nebulisation, aerosol, oral or IV) improve clinically relevant end-points?
9 In infants presenting to hospital or hospitalised with bronchiolitis, does administration of adrenaline / epinephrine (nebulisation, IM or IV) improve clinically relevant end-points?
10 In infants presenting to hospital or hospitalised with bronchiolitis, does administration of nebulised hypertonic saline improve clinically relevant end-points?
11a. In infants presenting to hospital or hospitalised with bronchiolitis, does administration of systemic or local glucocorticoids (nebulisation, oral, IM or IV) improve clinically relevant end-points?
11b. In infants presenting to hospital or hospitalised with bronchiolitis, with a positive response to Beta2 Agonists, does administration of systemic or local glucocorticoids (nebulisation, oral, IM or IV) improve clinically relevant end-points?
11c. In infants presenting to hospital or hospitalised with bronchiolitis, does administration of the combination of systemic or local glucocorticoids (nebulisation, oral, IM or IV) and adrenaline improve clinically relevant end-points?
12a. In infants presenting to hospital or hospitalised with bronchiolitis, does administration of supplemental oxygen improve clinically relevant end-points?
12b. In infants presenting to hospital or hospitalised with bronchiolitis, what level of oxygen saturation should lead to commencement or discontinuation of supplemental oxygen to improve clinically relevant end-points?
13. In infants hospitalised with bronchiolitis does continuous monitoring of pulse oximetry beneficially change medical management or clinically relevant end-points?
14. In infants hospitalised with bronchiolitis does the use of heated humidified high flow oxygen, or air, via nasal cannula improve clinically relevant end-points?
15. In infants hospitalised with bronchiolitis, does chest physiotherapy improve clinically relevant end-points?
16a. In infants hospitalised with bronchiolitis, does suctioning of the nose or nasopharynx improve clinically relevant end-points?
16b. In infants hospitalised with bronchiolitis, does deep suctioning in comparison to superficial suctioning beneficially improve clinically relevant end-points?
17 In infants hospitalised with bronchiolitis, does the use of nasal saline drops improve clinically relevant end-points?
18. In infants hospitalised with bronchiolitis, does the use of bubble CPAP improve clinically relevant end-points?
19. In infants hospitalised with bronchiolitis, is provision of home oxygen a safe alternative for management?
20a. In infants presenting to hospital or hospitalised with bronchiolitis, does the use of antibiotic medication improve clinically relevant end-points?
20b. In infants presenting to hospital or hospitalised with bronchiolitis, does the use azithromycin medication improve clinically relevant end-points?
20c. In infants presenting to hospital or hospitalised with bronchiolitis, does the use of antibiotic medication in infants who are at risk of developing bronchiectasis, improve clinically relevant end-points?
21a. In infants presenting to hospital or hospitalised with bronchiolitis, does the use of non-oral hydration improve clinically relevant end-points?
21b. In infants presenting to hospital or hospitalised with bronchiolitis, what forms of non-oral hydration improve clinically relevant end-points
21c. In infants presenting to hospital or hospitalised with bronchiolitis, does limiting the volume of non-oral hydration impact on clinical relevant end-points?
22 In infants presenting to hospital or hospitalised with bronchiolitis, do infection control practises improve clinically relevant end-points?